Table 1 Clinical characteristics of 67 patients with high-dose daptomycin therapy
Characteristica | Daptomycin dose (mg/kg) | ||
|---|---|---|---|
≤ 8 (n = 41) | > 8 (n = 26) | P value | |
Age, years | 56 (18–89) | 58.5 (22–87) | 0.57 |
Male (%) | 23 (56.1%) | 17 (65.4%) | 0.45 |
Weight, kg | 56 (37–89) | 61.5 (42–87) | 0.13 |
Creatinine clearance, mL/min | 38 (5–263) | 57.5 (10–210) | 0.54 |
Indwelling catheter useb | 31 (75.6%) | 16 (61.5%) | 0.22 |
Surgery within 3 months | 13 (31.7%) | 10 (38.5%) | 0.57 |
Underlying diseases | |||
Diabetes mellitus | 14 (34.1%) | 8 (30.8%) | 0.77 |
Cirrhosis of liver | 1 (2.4%) | 4 (15.4%) | 0.14 |
ESRD | 11 (26.8%) | 7 (26.9%) | 0.99 |
Heart failure | 11 (26.8%) | 11 (42.3%) | 0.19 |
Chronic lung disease | 5 (12.2%) | 3 (11.5%) | 0.94 |
Malignancy | 17 (41.5%) | 6 (23.1%) | 0.12 |
Charlson index | 4 (0–11) | 3.5 (0–11) | 0.46 |
Pitt bacteremia scorec | 4 (0–10) | 3 (0–7) | 0.85 |
ICU stay | 24 (58.5%) | 17 (65.4%) | 0.58 |
SOFA scored | 7 (2–17) | 8 (0–17) | 0.49 |
Ventilator use | 19 (46.3%) | 14 (53.8%) | 0.55 |
Previous anti-gram positive antibiotic | |||
Vancomycin | 28 (68.3%) | 22 (84.6%) | 0.14 |
Teicoplanin | 13 (31.7%) | 9 (34.6%) | 0.81 |
Linezolid | 5 (12.2%) | 4 (15.4%) | 0.71 |